Jeffrey Miller, MD
Professor of Medicine
Hematologist / Oncologist
- Blood Cancer
- Blood and Marrow Transplantation
- Blood and Marrow Transplant
- Masonic Cancer Clinic
Northwestern University Medical School
University of Iowa
University of Minnesota
E: Stephanie Thomas
P: (612) 626-4024
F: (612) 625-6919
Division of Hematology, Oncology and Transplantation
420 Delaware Street SE, MMC 480
Minneapolis, MN 55455
Jeffrey Miller, M.D. is Director of the Masonic Cancer Center Cell Therapy Core Laboratory at the University of Minnesota. Dr. Miller received a bachelor of science degree from Northwestern University in Evanston, Ill., and a medical degree from Northwestern University School of Medicine in 1985. He completed an internship and residency in internal medicine at the University of Iowa in Iowa City. After completing a postdoctoral fellowship in hematology-oncology at the University of Minnesota, he joined the faculty in 1991. Dr. Miller was appointed Deputy Director of the Masonic Cancer Center in February 2012.
Dr. Miller's research team works in two areas that seek to understand fundamental issues regarding innate immune function: 1) How undifferentiated stem cells develop into functioning NK cell lymphocytes, and 2) How to manipulate NK cells to treat or prevent cancer relapse. A major emphasis is on natural killer (NK) cell development. Recently, receptors on NK cells have been identified that recognize class I MHC molecules. The hypothesis underlying current research efforts is that "self" MHC molecules influence the NK cell receptor repertoire during development. Laboratory evaluation and human clinical trials will test the hypothesis that a mismatch between NK receptor and class I alleles on recipient tumor will result in greater tumor kill.
The second major emphasis in Dr. Miller’s laboratory is based on pre-clinical and clinical studies to develop effective anti-tumor immunotherapies. Early studies focused on nonspecific immune stimulation using subcutaneous IL-2. Strong evidence suggests that this nonspecific therapy alone will be ineffective, and current efforts aim to target effectors specifically to tumor cells. For natural killer cells, current approaches include combined therapy with monoclonal antibodies and interleukin-2 to target therapy through antibody-dependent cellular cytotoxicity (ADCC). To target T-cells, we have initiated studies using cancer vaccines.